PharmaEssentia

• Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

  Collaborator, Phase 1, Recruiting, 15 people, 9 Apr 2026

• NCT06290765

  Phase 4, Withdrawn, 0 people, 4 Mar 2024

• NCT05467553

  Collaborator, Phase 2, Status unknown, 30 people, 20 Jul 2022

• NCT03165955

  Collaborator, Phase 1, Completed, 28 people, 24 May 2017

• NCT01949805

  Collaborator, Phase 3, Completed, 257 people, 25 Sept 2013

Sources: clinicaltrials.gov

• Type 1 interferon perturbates clonal competition by reshaping human blood development

  Grants or research support, 15 Sept 2026

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  Fees or honoraria, 12 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov